Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
27.2M
Number of holders
70
Total 13F shares, excl. options
20.4M
Shares change
-533K
Total reported value, excl. options
$105M
Value change
-$2.84M
Put/Call ratio
0.15
Number of buys
30
Number of sells
-27
Price
$5.16

Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q2 2024

89 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q2 2024.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 20.4M shares of 27.2M outstanding shares and own 74.95% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2.75M shares), Artal Group S.A. (2.51M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.07M shares), Samsara BioCapital, LLC (1.79M shares), Avidity Partners Management LP (1.67M shares), Point72 Asset Management, L.P. (1.47M shares), Flagship Pioneering Inc. (1.29M shares), VANGUARD GROUP INC (968K shares), Opaleye Management Inc. (865K shares), and Deep Track Capital, LP (828K shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.